Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE ALLERGY versus DIPHEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE ALLERGY versus DIPHEN.
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY vs DIPHEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist. It inhibits histamine release from mast cells and basophils, reducing allergic symptoms.
Diphenhydramine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors. It also exhibits anticholinergic, sedative, antiemetic, and local anesthetic effects.
Fexofenadine hydrochloride 60 mg orally twice daily or 180 mg orally once daily.
50 mg IV/IM every 4 hours as needed for nausea/vomiting; 25-50 mg PO every 4-6 hours as needed for nausea/vomiting or motion sickness; 25 mg PO 3-4 times daily for vertigo; 15.6-25 mg IM/IV for antiemetic in surgery; maximum 300 mg/day.
None Documented
None Documented
Clinical Note
moderateDiphenoxylate + Torasemide
"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Torasemide."
Clinical Note
moderateDiphenoxylate + Etacrynic acid
"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etacrynic acid."
Clinical Note
moderateDiphenoxylate + Furosemide
"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Furosemide."
Clinical Note
moderate14.4 hours (range 11-16 hours) in healthy adults; prolonged in renal impairment.
Terminal elimination half-life is 22–72 hours (mean 30–40 hours); increases with hepatic disease or enzyme inhibitors.
Primarily fecal (80%) and renal (11%) as unchanged drug.
Primarily hepatic metabolism; renal excretion of inactive metabolites accounts for ~70% of eliminated drug; biliary/fecal excretion accounts for ~30%.
Category A/B
Category C
Antihistamine
Antihistamine
Diphenoxylate + Bumetanide
"The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Bumetanide."